BIOLASE Technology, Inc. (NASDAQ: BLTI), the World's leading dental

laser manufacturer and distributor, has been named a finalist in the

Medical Devices category for the TechAmerica Orange County High-Tech

Innovation Awards. Now in its 19th year, this premier business event

celebrates excellence and achievement in the region's technology

industry, and honors local companies, individuals and products that

drive innovation in Orange County. This year's winners will be

announced at a dinner on June 14, 2012, at the Hilton in Costa Mesa,


"We received nearly 100 nominations including start-up innovators,

high-growth companies and established industry players from across

Orange County," said Bob Brunson, director, TechAmerica Orange County.

"We congratulate BIOLASE for rising to the finalist rank. This region

is home to groundbreaking innovators, including BIOLASE, that continue

to influence technology development throughout the rest of the world,

and we're excited to help highlight them."

Federico Pignatelli, Chairman and CEO, said, "Providing innovative and

disruptive technologies that advance the practice of dentistry and

medicine with a truly new and biological surgical device that is

leading to enhanced outcomes for far superior and safer patient

experiences, continues to be our focus at BIOLASE. We are delighted

that our Waterlase iPlus? all-tissue dental laser system is a finalist

for innovative product/technology in the medical devices category. The

Waterlase iPlus, our flagship laser, is the most advanced laser ever

produced for dentistry and, with its tremendous cutting speed and

graphical intuitive user interface, addresses a wide range of clinical

procedures and can truly change the practice and economics of


For more information, please visit

About TechAmericaTechAmerica is the leading voice for the U.S.

technology industry -- the driving force behind productivity growth

and jobs creation in the United States and the foundation of the

global innovation economy. Representing approximately 1,000 member

companies of all sizes from the public and commercial sectors of the

economy, it is the industry's largest advocacy organization and is

dedicated to helping members' top and bottom lines. TechAmerica is

also the technology industry's only grassroots-to-global advocacy

network, with offices in state capitals around the United States,

Washington, D.C., Europe (Brussels) and Asia (Beijing). Learn more

about TechAmerica at

About BIOLASE Technology, Inc.BIOLASE Technology, Inc., the World's

leading Dental Laser Company, is a medical technology company that

develops, manufactures and markets dental lasers and also distributes

and markets dental imaging equipment, products that are focused on

technologies that advance the practice of dentistry and medicine. The

Company's laser products incorporate 285 patented and patent pending

technologies designed to provide clinically superior performance with

less pain and faster recovery times. Its imaging products provide

cutting-edge technology at competitive prices to deliver the best

results for dentists and patients. BIOLASE's principal products are

dental laser systems that perform a broad range of dental procedures,

including cosmetic and complex surgical applications, and a full line

of dental imaging equipment. BIOLASE has sold more than 19,000 lasers

among 16,000 customers. Other products under development address

ophthalmology and other medical and consumer markets.

For updates and information on laser and Waterlase dentistry, find

BIOLASE at, Twitter at, and

YouTube at

This press release may contain forward-looking statements within the

meaning of safe harbor provided by the Securities Reform Act of 1995

that are based on the current expectations and estimates by BIOLASE

management. These forward-looking statements can be identified through

the use of words such as "anticipates," "expects," "intends," "plans,"

"believes," "seeks," "estimates," "may," "will," and variations of

these words or similar expressions. Forward-looking statements are

based on management's current, preliminary expectations and are

subject to risks, uncertainties and other factors which may cause the

Company's actual results to differ materially from the statements

contained herein, and are described in the Company's reports it files

with the Securities and Exchange Commission, including its annual and

quarterly reports. No undue reliance should be placed on

forward-looking statements. Such information is subject to change, and

BIOLASE undertakes no obligation to update such statements.